What Aurobindo Pharma does

Aurobindo Pharma Limited is a Hyderabad-headquartered, publicly listed Indian pharmaceutical company founded in 1986 by P.V. Ram Prasad Reddy and K. Nityananda Reddy. It operates a vertically integrated platform spanning Active Pharmaceutical Ingredients (API), oral solids, injectables, liquids, biosimilars, OTC consumer health, and contract biologics manufacturing, organized through subsidiaries including APUSA, Aurolife, AuroHealth, Acrotech Biopharma, Vespyr Brands, Eugia, CuraTeQ Biologics, Apitoria, and the newly launched TheraNym Biologics CDMO.

The company runs 29 manufacturing facilities globally across India, the United States, Portugal, Brazil, and France, with annual capacities of 50+ billion formulation units and 19,000+ MT of APIs. It holds 830 US ANDA filings with 600+ approvals and facility accreditations from USFDA, EMA, UK MHRA, WHO, Health Canada, ANVISA, TGA, Japan PMDA, and GCC. Product reach spans 150+ countries; the company is ranked #1 in US generic oral solids by prescriptions (IMS, April 2024) and top 10 in 8 European countries (IQVIA MAT Q3 2024). The biosimilars pipeline, anchored by Bevqolva (bevacizumab), is approved in India, Canada, and the UK with EMA review ongoing, and TheraNym operates a Rs 1,200 crore biologics CDMO facility with MSD as anchor customer.

The business model is primarily B2B pharmaceutical distribution: generic formulations are sold through wholesale, retail pharmacy, government, and emerging-market channels, with vertical integration ensuring roughly half of formulation API needs are sourced in-house. Revenue in FY26 reached Rs 33,653 crore across US formulations (largest segment but declining 13% YoY in Q4), European formulations (crossing €1B annually, +30.2% YoY), Growth Markets (+24.7% YoY), ARVs for PEPFAR (3-4 million patients), specialty/injectables via Eugia, biosimilars via CuraTeQ, biologics CDMO via TheraNym, and consumer health brands via Vespyr. Recent capital deployment includes the $250M Lannett acquisition (FTC approved June 2026), $317M Khandelwal Laboratories acquisition, the Rs 800 crore share buyback (April 2026), and an Rs 1,200 crore TheraNym capex, signaling a pivot toward biologics, complex generics, and US manufacturing consolidation.

Name

Aurobindo Pharma

Legal name

Aurobindo Pharma Limited

Website

https://aurobindo.com

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Aurobindo Pharma is a vertically integrated Indian generic pharmaceutical manufacturer operating 29 global facilities, 830 US ANDA filings, and #1 US generic oral solids franchise. It serves US, Europe, Growth Markets, PEPFAR/HIV programs, and emerging biologics CDMO customers across 150+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Biosimilars manufacturing
• Biologics CDMO services
• Specialty injectable formulations

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. US Generic Formulations: Aurobindo Pharma USA (APUSA) generates revenue through sales of generic oral solid dosages and other generic pharmaceutical products distributed through its subsidiary network. The US business declined 13% YoY to Rs 3,543 crore in Q4 FY26 due to lower transient sales but remains the largest market segment.
2. European Formulations: Revenue from generic formulations sold across European markets. European formulations revenue grew 30.2% YoY to Rs 2,795 crore in Q4 FY26, with the European business crossing €1 billion in annual revenue during FY26. Company is ranked among top 10 generic companies in 8 European countries.
3. Growth Markets: Revenue from sales in emerging and developing markets outside US and Europe, growing 24.7% YoY to Rs 980 crore in Q4 FY26.
4. Active Pharmaceutical Ingredients (API): Revenue from manufacturing and sale of APIs, with almost half of the API requirements for formulations sourced in-house, demonstrating vertical integration benefits.
5. Specialty/Complex Generics: Revenue from Eugia (specialty products) and complex generics including non-opioid controlled substances. Through the Lannett acquisition, the company gains expertise in complex generic pharmaceuticals.
6. Biologics CDMO: Contract manufacturing organization services through TheraNym Biologics for global pharmaceutical companies, with MSD (Merck & Co.) as anchor customer. Represents new revenue stream from biologics contract manufacturing.
7. Anti-Retroviral (ARV) Drugs: Revenue from HIV/AIDS medications supplied through PEPFAR program to low- and middle-income countries. Company was first generic to develop dolutegravir and combination TLD, serving 3-4 million patients globally.

Pricing tiers

Go-to-market motion3 records

Distribution channels10 records

Marketing channels3 records

Core offering

Aurobindo Pharma is an integrated global pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars, specialty injectables, and over-the-counter health products across 150+ countries. The company operates 29 manufacturing facilities globally with 50+ billion formulation units and 19,000+ MT APIs annual capacity, with a portfolio of 830 US ANDA filings and 600+ approvals spanning CNS, ARV, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergy therapeutic areas. The company also operates a dedicated biologics contract development and manufacturing organization (TheraNym Biologics) and supplies anti-retroviral drugs to low- and middle-income countries through the PEPFAR program.

Product overview

Aurobindo Pharma is an integrated global pharmaceutical company operating as a platform of specialized business units across the pharmaceutical value chain. The portfolio includes APUSA as the US sales and marketing arm with subsidiaries Aurolife Pharma (manufacturing), AuroHealth (OTC distribution), Acrotech Biopharma (specialty oncology/dermatology), and Vespyr Brands (consumer OTC); Eugia for specialty products; CuraTeQ Biologics for biosimilars; Apitoria for APIs; and a dedicated ARV program for HIV/AIDS through PEPFAR. The company operates 29 manufacturing facilities globally with capacity of 50+ billion formulation units and 19,000+ MT APIs, serving 150+ markets. TheraNym Biologics CDMO represents the company's expansion into biologics contract manufacturing. Product offerings span oral solids, injectables, liquids, OTC products, APIs, and biosimilars across CNS, cardiovascular, anti-infectives, gastroenterology, anti-diabetics, and anti-allergy therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• ADQUEY: Difamilast 1% Ointment - dermatology product approved by FDA
• TheraNym
• Cold-EEZE
• MidNite
• Geritol
• Vivarin
• Balneol
• Contac
• Feosol
• Acrotech Biopharma
• Eugia
• CuraTeQ
• Apitoria
• Bevqolva

Products and services

• Generic Pharmaceuticals Portfolio Wide range of generic pharmaceutical formulations spanning seven major therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic. Includes 830 US ANDA filings with 600+ approvals; sold to wholesalers, pharmacies, supermarkets, and government agencies across the US, Europe, and Growth Markets.
• Bevqolva (Bevacizumab Biosimilar) Bevacizumab biosimilar for cancer treatment approved by CDSCO (India) and Health Canada, with EMA review ongoing. Available in 100mg/4mL and 400mg/16mL vial presentations for treating metastatic carcinoma of the colon or rectum and multiple cancers including colorectal and lung cancer.
• Tofacitinib Tablets Generic version of Pfizer's Xeljanz for autoimmune conditions, approved in 5 mg and 10 mg strengths by US FDA; targets US market estimated at approximately $494 million.
• Pomalidomide Capsules Pomalidomide capsules for multiple myeloma treatment, launched in the US market through Eugia Pharma Specialities.
• Everolimus Tablets Everolimus tablets in multiple strengths for oncology and transplant indications, approved by USFDA through Eugia Pharma Specialities.
• Dapagliflozin Tablets and Dapagliflozin/Metformin HCl ER Tablets Dapagliflozin (5 mg and 10 mg) and Dapagliflozin/Metformin Hydrochloride Extended-Release Tablets for the treatment of type 2 diabetes, approved by USFDA.
• Dextromethorphan Polistirex Extended-Release Oral Suspension Dextromethorphan Polistirex Extended-Release Oral Suspension 30mg/5mL, an over-the-counter product for cough relief, approved by USFDA.
• Glycerol Phenylbutyrate Oral Liquid Glycerol Phenylbutyrate Oral Liquid (1.1 grams per mL), a Ravicti generic equivalent, approved by USFDA.
• ADQUEY (Difamilast 1% Ointment) Difamilast 1% Ointment for atopic dermatitis treatment, FDA-approved through Acrotech Biopharma.
• Anti-Retroviral (ARV) Products HIV/AIDS medications supplied through the PEPFAR program to low- and middle-income countries. Aurobindo was the first generic company to develop dolutegravir and TLD combination, with capacity to supply treatment to 3-4 million patients globally.
• Vespyr OTC Wellness Brands Iconic OTC consumer health brands including Cold-EEZE (clinically proven to reduce common cold duration by 42%), MidNite (sleep aid), Geritol (vitamins/minerals, trusted 70+ years), Vivarin (alertness), Balneol (skincare), Contac (cold/flu), and Feosol (#1 pharmacist recommended iron supplement). Distributed via Walmart, Walgreens, CVS, and Amazon.
• Apitoria APIs (Active Pharmaceutical Ingredients) Large-scale Active Pharmaceutical Ingredient (API) manufacturing with 19,000+ MT annual capacity. Supplies APIs for in-house formulations and external customers, with strong expertise in process chemistry. Almost half of Aurobindo's API requirements for formulations are sourced in-house.
• TheraNym Biologics CDMO Services Contract Development and Manufacturing Organization (CDMO) services for biologics manufacturing at the Borapatla, Telangana facility. Equipped with 15 KL bioreactors and aseptic fill-finish capabilities, serving global pharmaceutical innovators including MSD (Merck & Co.) as anchor customer. Expected to manufacture advanced therapeutics for cancer and other life-threatening diseases.
• Eugia Specialty Products (Injectables and Complex Generics) Specialty pharmaceutical products division manufacturing complex generics including injectables, liquids, and other specialty formulations. Operates multiple manufacturing facilities in India at Pashamylaram, Shameerpet, and other locations.
• Acrotech Biopharma Specialty Pharmaceuticals Specialty pharmaceutical company focusing on oncology and dermatology. Markets five injectable oncology brands in the USA and is a leader in Peripheral T-Cell Lymphoma. Prepares to commercialize biosimilar pipeline in immuno-oncology space.

Quantifiable outcome

• European business crossed €1 billion annual revenue in FY26
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• STADA Arzneimittel AGcoreStrategic or Co-development Partner · 23 June 2026CuraTeQ Biologics, Aurobindo's biosimilars subsidiary, entered a partnership with STADA Arzneimittel AG to distribute biosimilars in key European markets including France and Germany. This strategic alliance expands Aurobindo's biosimilar footprint in Europe leveraging STADA's regional market knowledge and distribution capabilities.
• Quagen PharmaceuticalsminorOthers · 18 June 2026As a condition of FTC approval for the Lannett acquisition, Aurobindo was required to divest four generic drug products (mycophenolate mofetil, pilocarpine, rabeprazole, and niacin extended release) to Quagen Pharmaceuticals. These products contributed approximately 6-7% of Lannett's revenue.
• MSD (Merck & Co.)coreStrategic or Co-development Partner · 12 June 2026MSD (Merck & Co.) serves as the anchor customer for TheraNym Biologics, Aurobindo's dedicated biologics contract manufacturing organization inaugurated in Borapatla near Hyderabad. MSD's partnership validates Aurobindo's biologics manufacturing capabilities and positions TheraNym as a trusted CDMO partner for global pharmaceutical innovators.
• US Government (FDA/USDA)coreOthers · 11 June 2026Indian pharmaceutical companies including Aurobindo Pharma are in advanced discussions with US authorities to supply ifosfamide injection, a critical chemotherapy drug, to address ongoing drug shortage in the US. The FDA reached out to Indian pharmaceutical bodies requesting manufacturers capable of producing the drug in 1g and 3g strengths.
• Lannett Company LLCcoreStrategic or Co-development Partner · 1 July 2025Aurobindo Pharma USA received FTC approval to acquire Pennsylvania-based Lannett Company LLC for $250 million on a cash-free, debt-free basis. The acquisition adds 113 approved ANDAs, a Seymour, Indiana manufacturing facility with 4 billion doses capacity, and expertise in complex non-opioid controlled substances. Expected to be immediately accretive to EPS and contribute up to $500 million in revenue.
• Khandelwal LaboratoriesminorStrategic or Co-development Partner · 1 January 2024Aurobindo completed payment for the $317 million acquisition of Khandelwal Laboratories' non-oncology business, expanding its product portfolio and market presence in the Indian domestic market.
• VeritazminorStrategic or Co-development Partner · 1 April 2022Aurobindo Pharma acquired the domestic formulations business of Veritaz for Rs 171 crore, effective April 1, 2022. The acquisition helped expand Aurobindo's presence in the Indian pharmaceutical market, particularly in biosimilars and other products, utilizing Veritaz's distribution network and product portfolio.

Scale indicators21 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• Sun Pharmaceutical Industries: Largest Indian pharma company by revenue, with overlapping generics, specialty (including Tofacitinib competing with Aurobindo's recent approval), API, and biosimilar businesses. Comparable business model with global manufacturing footprint and US focus.
• Lupin Limited: Indian-headquartered peer in generic formulations, APIs, and specialty products with significant US presence. Overlapping focus on complex generics, biosimilars, and emerging markets.
• Cipla: Major Indian generics competitor with strong ARV/HIV portfolio (overlapping with Aurobindo's PEPFAR business), US generics, and emerging markets focus. Comparable respiratory and complex generic product portfolios.
• Dr. Reddy's Laboratories: Direct Indian-headquartered competitor in generic formulations, APIs, and biosimilars across US, Europe, and emerging markets. Aurobindo surpassed Dr. Reddy's in FY26 revenue race (₹33,653 crore vs ₹33,593 crore), making them the closest comparable peer.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with significant US and Canadian presence. Comparable vertically integrated generic formulations and API manufacturing.
• STADA Arzneimittel AG: European-focused generics and consumer healthcare company and direct partner of Aurobindo for biosimilars distribution in France/Germany. Comparable specialty generics and biosimilars business model.
• Zydus Lifesciences: Indian pharmaceutical company with US generics, APIs, biosimilars (similar to Bevqolva), and specialty business. Direct competitor across multiple therapeutic segments and geographies.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad portfolio across oral solids, injectables, and biosimilars. Direct competitor in US generic oral solids where Aurobindo is #1 by prescriptions.
• Viatris: Global pharmaceutical company formed from Mylan-Upjohn merger with substantial generics, biosimilars, and complex generics portfolios. Comparable product breadth and US distribution scale.
• Sandoz (Novartis): Global generics and biosimilars division of Novartis with leading European generics presence. Direct competitor in European generic formulations where Aurobindo ranks top-10 across 8 countries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/aurobindoglobal
• LinkedInlinkedin.com/company/aurobindo-pharma
• Facebookfacebook.com/login.php

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries15 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurobindo Pharma